Loading
A phase 2 trial of Bladder EpiCheck urine methylation test in Non-muscle-invasive bladder cancer, run by White River Junction Veterans Affairs Medical Center, now recruiting.
Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance is a phase 2 interventional study registered as NCT05796375 by White River Junction Veterans Affairs Medical Center, with 240 participants planned, started 2023-11-17 and due to reach its primary completion in 2028-11-30. Interventions recorded: Cystoscopy, Bladder EpiCheck urine test, Xpert Bladder Cancer Monitor urine test. Conditions recorded: Non-muscle-invasive Bladder Cancer.
Linked to the technology Bladder EpiCheck urine methylation test because the registry names it ("epicheck") among its interventions and Non-muscle-invasive bladder cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Shares Non-muscle-invasive bladder cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/